Results 271 to 280 of about 79,208 (292)

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

Blood Cancer Journal, 2011
Kotaro Shide
exaly  

The JAK2 V617F mutation in de novo acute myelogenous leukemias

Oncogene, 2005
W S Min, N J Yoo, Y G Kim
exaly  

Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia†

International Journal of Cancer, 2011
Phillip Koeffler, Takayuki Ikezoe, Chie Nishioka   +2 more
exaly  

JAK2

2008
openaire   +1 more source

Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?

British Journal of Haematology, 2014
Barbara J Bain
exaly  

Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway

Journal of Cellular and Molecular Medicine, 2012
Wan Du, Wen-Yu Su, Ying-Chao Wang
exaly  

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

Blood, 2010
Brian Druker, Emmanuelle Fantino, Jeffrey W. Tyner   +2 more
exaly  

Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies

Current Oncology Reports, 2009
Peter P Sayeski, Jacqueline Sayyah
exaly  

Top bar navigation

Frontiers in Oncology, 2022
exaly  

People also looked at

Frontiers in Pharmacology, 2018
Shiow-Lin Pan, Chao-Di Chang, Wei-Chun Huangfu   +2 more
exaly